Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VANTA BIOSCIENCE vs CROWN LIFTERS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VANTA BIOSCIENCE CROWN LIFTERS VANTA BIOSCIENCE/
CROWN LIFTERS
 
P/E (TTM) x - - - View Chart
P/BV x 3.8 2.0 195.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VANTA BIOSCIENCE   CROWN LIFTERS
EQUITY SHARE DATA
    VANTA BIOSCIENCE
Mar-20
CROWN LIFTERS
Mar-20
VANTA BIOSCIENCE/
CROWN LIFTERS
5-Yr Chart
Click to enlarge
High Rs19544 448.3%   
Low Rs8030 267.6%   
Sales per share (Unadj.) Rs21.269.1 30.6%  
Earnings per share (Unadj.) Rs1.6-16.9 -9.5%  
Cash flow per share (Unadj.) Rs3.515.5 22.5%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs37.279.1 47.0%  
Shares outstanding (eoy) m6.312.08 303.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x6.50.5 1,221.8%   
Avg P/E ratio x85.7-2.2 -3,934.9%  
P/CF ratio (eoy) x39.42.4 1,667.7%  
Price / Book Value ratio x3.70.5 796.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m86876 1,135.8%   
No. of employees `000NANA-   
Total wages/salary Rs m3919 204.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m134144 93.0%  
Other income Rs m11 141.0%   
Total revenues Rs m135145 93.2%   
Gross profit Rs m4465 66.9%  
Depreciation Rs m1267 17.6%   
Interest Rs m1936 53.4%   
Profit before tax Rs m13-38 -35.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3-3 -123.2%   
Profit after tax Rs m10-35 -28.9%  
Gross profit margin %32.745.5 71.9%  
Effective tax rate %24.57.1 346.6%   
Net profit margin %7.6-24.4 -31.1%  
BALANCE SHEET DATA
Current assets Rs m20089 225.0%   
Current liabilities Rs m10076 131.8%   
Net working cap to sales %74.68.9 836.9%  
Current ratio x2.01.2 170.7%  
Inventory Days Days260-  
Debtors Days Days38139 27.4%  
Net fixed assets Rs m287403 71.2%   
Share capital Rs m6321 303.2%   
"Free" reserves Rs m172144 119.4%   
Net worth Rs m235165 142.6%   
Long term debt Rs m137273 50.0%   
Total assets Rs m487492 99.0%  
Interest coverage x1.70 -4,774.8%   
Debt to equity ratio x0.61.7 35.1%  
Sales to assets ratio x0.30.3 93.9%   
Return on assets %6.10.3 2,159.7%  
Return on equity %4.3-21.3 -20.2%  
Return on capital %8.9-0.3 -3,015.0%  
Exports to sales %51.40-   
Imports to sales %0.80-   
Exports (fob) Rs m69NA-   
Imports (cif) Rs m1NA-   
Fx inflow Rs m690-   
Fx outflow Rs m30-   
Net fx Rs m650-   
CASH FLOW
From Operations Rs m2311 212.0%  
From Investments Rs m-74-1 7,905.4%  
From Financial Activity Rs m19-8 -230.3%  
Net Cashflow Rs m-312 -1,817.2%  

Share Holding

Indian Promoters % 69.0 73.5 93.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 31.0 26.5 116.9%  
Shareholders   412 195 211.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VANTA BIOSCIENCE With:   APTUS INDUSTRIES  VIMTA LABS  SANGHVI BRANDS   CROWN LIFTERS   TRISHAKTI ELEC.  



Today's Market

Sensex Snaps 2-Day Losing Streak, Zooms 887 Points, Nifty Settles Above 17,150; Tata Steel, Axis Bank Top Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VANTA BIOSCIENCE SHARE PRICE


Dec 7, 2021 03:36 PM

TRACK VANTA BIOSCIENCE

  • Track your investment in VANTA BIOSCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VANTA BIOSCIENCE

VANTA BIOSCIENCE - LYNX MACH. COMPARISON

COMPARE VANTA BIOSCIENCE WITH

MARKET STATS